Glaukos : Investor Presentation May 2025

Published: 2025-05-14 07:15:18 ET GKOS

Published on 05/14/2025 at 07:15

GLAUK

TRANSFORMING VISION

May 2025

WE'LL GO

FIRST

CORE GROWTH STRATEGY

Leading-edge Innovation

Pursuing big ideas that address clinical needs of large and/or underserved patient populations

Dropless Therapies

Challenging conventional paradigms to advance the standards of care and improve outcomes

Commercial Excellence

Building durable new markets to better serve physicians and patients worldwide

Innovation is at the core of everything we do. At Glaukos, we push the limits of science and technology to solve unmet needs in chronic eye diseases for the benefit of patients worldwide.

FIVE NOVEL PLATFORMS

Micro-scale surgical devices

Sustained-release pharmaceuticals

Bio-activated pharmaceuticals

Transdermal pharmaceuticals

Bio-erodible IVT pharmaceuticals

FOUR THERAPEUTIC AREAS

Full scope of disease progression

Keratoconus

Dry Eye, Presbyopia, Demodex Blepharitis, Progressive Myopia

AMD, DME, RVO

INDUSTRY-LEADING INNOVATION

Invested in R&D since 2018

Ocular Hypertension and Open-Angle Glaucoma

AMD DME RVO

Disclosed pipeline programs in 2025 vs. 4 in 2015

Blepharitis

Presbyopia Glaucoma Dry Eye

Keratoconus

2025-26 KEY

COMMERCIAL CATALYSTS

Focused on establishing robust growth engines centered on proven, foundational therapies that improve the standard of care

iLinko2n with Epioxa is not approved by the FDA

iDose® TR

iStent infinite®

iLinko2n with EpioxaTM

Disclaimer

Glaukos Corporation published this content on May 14, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 14, 2025 at 11:14 UTC.